Eptifibatide - EPARs for authorised medicinal products for human use - Integrilin

FICHA FARMACOLÓGICA de Eptifibatide. Contiene la Monografía en distintos idiomas (de la Unión Europea), así como la discusión científica que sustenta su aprobación terapéutica. Para acceder a la monografía en idioma español, hacer doble clik en la sigla (es) en la fila que se sitúa más abajo del centro de la página oficial. Se recuerda que todas las informaciones científico-clínicas, así como técnicas propias de la producción, sólo se publican en idioma inglés. Cerasale. MARZO 04, 2010.-

abrir aquí para acceder al documento EMA completo:
EPARs for authorised medicinal products for human use - Integrilin

Active Substance
Eptifibatide
International Nonproprietary Name or Common Name
Eptifibatide
Pharmaco-therapeutic Group
Antithrombotic Agent (platelet aggregation inhibitor excl. heparin)
ATC Code
B01AC16

Therapeutic Indication
Integrilin is intended for use with acetylsalicylic acid and unfractionated heparin.

Integrilin is indicated for the prevention of early myocardial infarction in patients presenting with unstable angina or non-Q-wave myocardial infarction with the last episode of chest pain occurring within 24 hours and with ECG changes and/or elevated cardiac enzymes.

Patients most likely to benefit from Integrilin treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early PTCA (Percutaneous Transluminal Coronary Angioplasty) (see section 5.1).

Date of issue of Marketing Authorisation valid throughout the European Union
1 July 1999

Orphan medicinal product designation date
Not applicable


EPARs for authorised medicinal products for human use